Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
K-232 52-week phase 3 study in glaucoma and ocular hypertension
jRCT2080225063Phase 3Completed
- Sponsor
- Kowa Company, Ltd.
- Start
- Feb 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of K-232 in open-angle glaucoma (OAG), pseudoexfoliation glaucoma (PXG), pigmentary glaucoma (PG) and 1 more (2 arms), sponsored by Kowa Company, Ltd. Primary endpoints: 52-week intraocular pressure-lowering efficacy and 52-week safety of K-232. Started Feb 2020; status: completed.
02
Drugs
K-232
03
Conditions
open-angle glaucoma (OAG)pseudoexfoliation glaucoma (PXG)pigmentary glaucoma (PG)ocular hypertension
Beyond the preview
Go deeper on jRCT2080225063.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080225063.